Evolve Biosystems Stock
Evolve BioSystems is developing the next generation of products to establish, restore, and maintain a healthy newborn gut microbiome.
Sign up today and learn more about Evolve Biosystems Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Evolve Biosystems Stock
Evolve Biosystems is a spin-out from the Foods For Health Institute (FFHI) at the University of California, Davis. The company builds on more than a decade of research into the infant biome and its intimate interaction with breast milk components established by the founding scientists including Bruce German, David Mills, Carlito Lebrilla, Daniela Barile and Samara Freeman. Their fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004.
Investors
Bill & Melinda Gates Foundation
Apeel Sciences, Pivot Bio, Butterfly Network, Schrodinger, Evolve Biosystems, Heliogen
Funding History
August 2015 | $9.0M |
---|---|
May 2017 | $20.0M |
June 2018 | $40.0M |
Management
Director, IP & Regulatory Affairs
Samara Freeman
Co-Founder
Carlito Lebrilla
CEO
David Kyle
Co-Founder
Bruce German
Co-Founder
David Mills
Co-Founder
Daniela Barile
Press
prnewswire - Oct, 4 2022
Evolve Biosystems becomes Infinant Health - powerful evolution of mission, leadership, portfolio & commercialization strategy to transform the future of human health under new corporate identitybiospace - Oct, 3 2022
Evolve Biosystems becomes Infinant Healthprnewswire - Oct, 1 2019
Evolve BioSystems And The Regents Of The University Of California Jointly File Patent Infringement Complaint Against Abbott Laboratories Regarding Infant Probioticdealstreetasia - Jun, 14 2018
Li Ka-Shing’s Horizon Ventures co-leads $40m round in infant probiotic firm EvolveGlobal University Venturing - Jun, 14 2018
Evolve BioSystems digests $40m series C